Junshi Biosciences Sustainability Profile
Junshi Biosciences, officially known as Junshi Pharmaceutical Co., Ltd., is a leading biopharmaceutical company headquartered in China. Founded in 2012, the company has rapidly established itself in the global biotechnology landscape, focusing on the research, development, and commercialisation of innovative therapies, particularly in oncology and autoimmune diseases. With a strong presence in major operational regions including Asia and North America, Junshi Biosciences is recognised for its cutting-edge monoclonal antibody products. Notably, its flagship product, toripalimab, has garnered significant attention for its unique mechanism of action in cancer treatment. The company has achieved remarkable milestones, including successful partnerships and regulatory approvals, positioning itself as a key player in the biopharmaceutical industry.
DitchCarbon Score
How does Junshi Biosciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Junshi Biosciences's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Junshi Biosciences's reported carbon emissions
In 2024, Junshi Biosciences reported total carbon emissions of approximately 26,800,750 kg CO2e. This figure includes about 5,307,750 kg CO2e from Scope 1 emissions and approximately 21,493,000 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data. Comparatively, in 2019, Junshi Biosciences' total emissions were about 11,319,000 kg CO2e, with Scope 1 emissions at approximately 3,562,000 kg CO2e and Scope 2 emissions at around 7,757,000 kg CO2e. This indicates a significant increase in emissions over the five-year period. Currently, Junshi Biosciences has not set any specific reduction targets or initiatives, nor have they committed to any climate pledges. The absence of such commitments may reflect a broader industry context where many companies are still developing their sustainability strategies. The emissions data is not cascaded from any parent company, and all figures are sourced directly from Junshi Biosciences.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2024 | |
|---|---|---|
| Scope 1 | 3,562,000 | 0,000,000 |
| Scope 2 | 7,757,000 | 00,000,000 |
| Scope 3 | - | - |
How Carbon Intensive is Junshi Biosciences's Industry?
How Carbon Intensive is Junshi Biosciences's Location?
Junshi Biosciences's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Junshi Biosciences has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
